Document Detail


Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study.
MedLine Citation:
PMID:  9918247     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate whether serial anticardiolipin determination contributes to the clinical management of patients with systemic lupus erythematosus (SLE) with no previous sign of the antiphospholipid syndrome (APS). METHODS: In 90 patients with SLE with no previous clinical manifestations of the APS, repeated clinical evaluations were performed, and serial blood samples (obtained over a 30 month period, range 13-53 mo) were screened for antiphospholipid antibodies (aPL). Anticardiolipin antibodies (aCL) were detected using an ELISA and considered positive if the result was >25 GPL on 2 separate occasions. Patients were not required to be on a specific treatment regimen during the study. RESULTS: Thirty-four patients (37%) had at least one positive ELISA and 11 (11/90, 12%) 2 positive ELISA for IgG aCL during the study. Lupus anticoagulant (LAC) was found in 16 patients, and a false positive VDRL in 5. At study completion, the total number of clinical or laboratory events associated with APS was 30. In univariate analysis, aCL was significantly associated only with LAC (p<0.012). Presence of aCL also correlated with hemoglobin level, anti-DNA antibody, leukocyte count, and the SLE Disease Activity Index (SLEDAI). LAC and aCL were significantly associated with each other (OR 5.17; 95% CI 1.5-17.7), but LAC had a better positive predictive value than aCL for arterial thrombosis and neurological events. CONCLUSION: Among our patients with SLE without previous clinical manifestations of APS, positive aCL did not predict the occurrence of APS within the next 3 years, but was statistically related to the clinical disease activity (SLEDAI).
Authors:
M de Bandt; K Benali; L Guillevin; E Hachulla; C Job; B Fautrel; G Fournié; C Bonnet; B Fournié; P Le Goff; C Jorgensen; O Meyer
Related Documents :
12115187 - Role of the fcgamma receptor iia polymorphism in susceptibility to systemic lupus eryth...
6732407 - Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia.
22236357 - Determinants of condom uptake among hiv voluntary counselling and testing clients: expe...
24792137 - Applied anatomy of small branches of the portal vein in transverse groove of hepatic hi...
9719247 - Drug-induced pneumonitis caused by sulfamethoxazole, trimethoprim during treatment of p...
24999477 - Lead screening for cxcr4 of the human hiv infection receptor inhibited by traditional c...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  The Journal of rheumatology     Volume:  26     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-03-23     Completed Date:  1999-03-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  CANADA    
Other Details:
Languages:  eng     Pagination:  91-6     Citation Subset:  IM    
Affiliation:
Rheumatology Unit, Bichat Teaching Hospital, Paris, France. debandt@bichat.inserm.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Antibodies, Antiphospholipid / analysis,  blood*
Antiphospholipid Syndrome / blood*
Child
Cohort Studies
Female
Humans
Longitudinal Studies
Lupus Erythematosus, Systemic / blood*,  metabolism
Male
Middle Aged
Prospective Studies
Chemical
Reg. No./Substance:
0/Antibodies, Antiphospholipid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Distribution of lupus anticoagulant and anticardiolipin antibody isotypes in a population with antip...
Next Document:  Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythemat...